Press Releases Subscribe to our News
Non-Regulatory
Biosergen will present at Aktiespararnas Småbolagsdagarna June 13, 2023
Non-Regulatory
Biosergen will be participating in Investerarträff arranged by Financial Stockholm, March 29
Non-Regulatory
Biosergen will be participating at Mangold Insight Investor Day, March 22
Non-Regulatory
Carlsquare has initiated its coverage of Biosergen
Non-Regulatory
Positive topline data from phase 1 study of BSG005 shows it is safe and well tolerated. It gives hope for a change in the treatment paradigm of patients with invasive fungal infections.
ReleaseNon-Regulatory
Biosergen completes the first Multiple Ascending Dose (MAD) cohort of BSG005 phase I trial
ReleaseNon-Regulatory
The first volunteer has been dosed in the MAD part of the Phase I trial of BSG005
ReleaseNon-Regulatory
Biosergen allocates shares to an underwriter in connection with the completed rights issue
ReleaseNon-Regulatory
The subscription period in Biosergen’s rights issue starts today
Non-Regulatory
Biosergen AB: Biosergen publishes prospectus due to rights issue of units
ReleaseEU-tillväxtprospekt - Biosergen
Non-Regulatory
3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.
ReleaseNon-Regulatory
Biosergen is preparing a Phase II study of BSG005 against Mucormycosis, the Black Fungus.
ReleaseNon-Regulatory
The first subjects dosed successfully with no adverse events in the phase I trial of BSG005
ReleaseNon-Regulatory
Biosergen’s application to start human clinical trials with BSG005 is approved
ReleaseNon-Regulatory
BIOSERGEN HAS BEEN APPROVED FOR LISTING ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM.
Biosergen listing approvalNon-Regulatory
The outbreak of mucormycosis (the so-called “Black Fungus”) in India is a prime example of the great need for a safer antifungal drug with true fungicidal activity
ReleaseNon-Regulatory
BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM
BIOSERGEN INTENDS TO LIST ITS SHARES ON NASDAQ FIRST NORTH GROWTH MARKET STOCKHOLM (PDF)Non-Regulatory
